Matthew Lunning, DO, on Ublituximab Plus TGR-1202 in Lymphoma
2014 ASH Annual MeetingMatthew Lunning, DO, of the University of Nebraska Medical Center, on abstract 801, “Ublituximab, a Novel Glycoengineered Anti-CD20 Monoclonal Antibody, in Combination with TGR-1202, a Next-Generation Once Daily PI3kδ Inhibitor, Demonstrates Activity in Heavily Pretreated and High-Risk Chronic Lymphocytic Leukemia and B-Cell Lymphoma.”
Related Videos
Sagar Lonial, MD, on Monoclonal Antibodies in Multiple Myeloma
Sagar Lonial, MD, of Winship Cancer Institute, offers his thoughts on abstract 302, “Final Resu...
Julie M. Vose, MD, MBA, FASCO, on Nivolumab in Relapsed/Refractory Hodgkin Lymphoma
Julie M. Vose, MD, MBA, FASCO, of the University of Nebraska Medical Center, offers her thoughts on abstract 289,
2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 380,
Linda J. Burns, MD, on CAR T-Cell Therapy in ALL
Linda J. Burns, MD, on a Phase II Study of ACE-536 in Beta-Thalassemia
2014 ASH President Linda J. Burns, MD, of the University of Minnesota, offers her thoughts on abstract 53,
Keith McCrae, MD, on Managing Heparin-Induced Thrombocytopenia
Keith McCrae, MD, of the Cleveland Clinic, offers his thoughts on abstract 4848, “Implementatio...
